Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib

JAMA oncology

Volumn 2, Issue 10, 2016, Pages 1287-1294

  Prat, Aleix ^a   Cheang, Maggie C U ^a   Galván, Patricia ^a   Nuciforo, Paolo ^a   Paré, Laia ^a   Adamo, Barbara ^a   Muñoz, Montserrat ^a   Viladot, Margarida ^a   Press, Michael F ^a   Gagnon, Robert ^a   Ellis, Catherine ^a   Johnston, Stephen ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; LAPATINIB; LETROZOLE; NITRILE; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NITRILES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES;

EID: 85013803835     PISSN: None     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.0922     Document Type: Article

References (0)